AI in drug discovery

News

Change at the top of Recursion as co-founder leaves CEO role

After 12 years as CEO of 'techbio' player Recursion, Chris Gibson is switching to the role of chair and will be replaced by Najat Khan.

News

Lilly partners NVIDIA to build 'most powerful' supercomputer

Eli Lilly and NVIDIA have joined forces on an ambitious plan – building pharma's most powerful AI-powered supercomputer for drug discovery.

News

Google claims quantum advance could speed up drug discovery

Google has claimed an advance in quantum computing that is a milestone towards its practical applications in areas like drug discovery.

News

Ignota's co-founder and chief executive, Sam Windsor

Ignota vacuums up Kronos Bio's drug programmes

Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

News

Three more pharmas join OpenFold3 AI consortium

Bristol Myers Squibb, Takeda, and Astex have joined a consortium working on refining the OpenFold structure prediction platform with industry data.

News

MSD's $349m alliance with Variational, and other AI news

MSD signs $345m alliance with Variational AI, plus updates on AI in drug discovery projects from Bio Protocol, Dalton Tx, Virginia Tech, and Insilico.

Change at the top of Recursion as co-founder leaves CEO role

Lilly partners NVIDIA to build 'most powerful' supercomputer

Google claims quantum advance could speed up drug discovery

Ignota vacuums up Kronos Bio's drug programmes

Three more pharmas join OpenFold3 AI consortium

MSD's $349m alliance with Variational, and other AI news

Doctors dismayed by report of NHS AI proposal

Discover a new era of healthcare panel engagement: Grounded ...

AI in drug discovery

Editor's Picks